Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Borodovsky

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Current Opinion in Oncology|November 15, 2011
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2Alexandra Borodovsky, Meghan J Seltzer, Gregory J Riggins
Expert Opinion on Drug Discovery|October 20, 2018
Targeting adenosine A<sub>2A</sub> receptor antagonism for treatment of cancerMiles Congreve, Giles A Brown, Alexandra Borodovsky, et al.
Neuro-Oncology|September 6, 2018
Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomideAlex Shimura Yamashita, Marina da Costa Rosa, Alexandra Borodovsky, et al.
Analytical Biochemistry|November 9, 2018
Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatizationKelly J Goodwin, Eric Gangl, Ujjal Sarkar, et al.
Molecular Cancer Therapeutics|November 8, 2014
Repurposing the antihelmintic mebendazole as a hedgehog inhibitorAndrew R Larsen, Ren-Yuan Bai, Jon H Chung, et al.
Journal of Neuro-Oncology|December 5, 2014
A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeresAlexandra Borodovsky, Alan K Meeker, Ewen F Kirkness, et al.
Oncotarget|October 1, 2013
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor DecitabineSevin Turcan, Armida W M Fabius, Alexandra Borodovsky, et al.
Frontiers in Immunology|March 19, 2021
Evaluation of Combination Strategies for the A<sub>2A</sub>R Inhibitor AZD4635 Across Tumor Microenvironment Conditions <i>via</i> a Systems Pharmacology ModelVeronika Voronova, Kirill Peskov, Yuri Kosinsky, et al.
Oncotarget|October 1, 2013
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograftAlexandra Borodovsky, Vafi Salmasi, Sevin Turcan, et al.
Molecular Cancer|December 8, 2017
Generation of stable PDX derived cell lines using conditional reprogrammingAlexandra Borodovsky, Travis J McQuiston, Daniel Stetson, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Current Opinion in Oncology|November 15, 2011
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2Alexandra Borodovsky, Meghan J Seltzer, Gregory J Riggins
Expert Opinion on Drug Discovery|October 20, 2018
Targeting adenosine A<sub>2A</sub> receptor antagonism for treatment of cancerMiles Congreve, Giles A Brown, Alexandra Borodovsky, et al.
Neuro-Oncology|September 6, 2018
Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomideAlex Shimura Yamashita, Marina da Costa Rosa, Alexandra Borodovsky, et al.
Analytical Biochemistry|November 9, 2018
Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatizationKelly J Goodwin, Eric Gangl, Ujjal Sarkar, et al.
Molecular Cancer Therapeutics|November 8, 2014
Repurposing the antihelmintic mebendazole as a hedgehog inhibitorAndrew R Larsen, Ren-Yuan Bai, Jon H Chung, et al.
Journal of Neuro-Oncology|December 5, 2014
A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeresAlexandra Borodovsky, Alan K Meeker, Ewen F Kirkness, et al.
Oncotarget|October 1, 2013
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor DecitabineSevin Turcan, Armida W M Fabius, Alexandra Borodovsky, et al.
Frontiers in Immunology|March 19, 2021
Evaluation of Combination Strategies for the A<sub>2A</sub>R Inhibitor AZD4635 Across Tumor Microenvironment Conditions <i>via</i> a Systems Pharmacology ModelVeronika Voronova, Kirill Peskov, Yuri Kosinsky, et al.
Oncotarget|October 1, 2013
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograftAlexandra Borodovsky, Vafi Salmasi, Sevin Turcan, et al.
Molecular Cancer|December 8, 2017
Generation of stable PDX derived cell lines using conditional reprogrammingAlexandra Borodovsky, Travis J McQuiston, Daniel Stetson, et al.
Pageof 2